ADMA Biologics Receives FDA Approval to Expand ASCENIV Label for Pediatric Patients
ADMA Biologics received FDA approval on May 4, 2026, to expand the label of its biologic treatment ASCENIV to include pediatric patients aged two years and older. This marks a significant milestone as it broadens the therapy's application beyond adults with primary humoral immunodeficiency.
Tickers: $ADMA
Topics: biotech immunology pharmaceuticals